+++
INTRODUCTION: KEY POINTS
++
++
Prior to transplantation:
++
Identify potential infectious issues in both donors and recipients.
Identify and evaluate both donors and recipients for past, present, and potential infections.
Confirm that recipients are properly vaccinated.
++
++
Some early recipient infections may be donor derived.
Recognizing the time course of infections provides useful information and should be carefully considered when predicting what infection may be present.
Prophylaxis and treatment of acute rejection may alter or frame-shift the timeline of when specific infections are expected to occur.
The severity of immunosuppression should be evaluated based on the patient’s:
Time from transplant
Type/dose of immunosuppression
Presence of recent rejection
Use of T-cell-inhibiting agents
Medical condition at the time of transplantation
++
Transplant recipients may present with altered inflammatory responses to infection.
Common infections may present in uncommon ways.
Clinicians must approach transplant patients with a high degree of suspicion for infection and consider that infection may be present until proven otherwise.
Concurrent infections (more than one single pathogen) are more likely in transplant patients than in the general nonimmunocompromised population.
The differential diagnosis of pathogens is more extensive in transplant patients than in nonimmunocompromised individuals.
Have a low threshold for both enhanced imaging studies and biopsies. Imaging studies and biopsies should be obtained early in order to make a prompt definitive diagnosis and establish an adequate therapeutic approach—if in doubt, image and biopsy. Early diagnosis also helps limit the use of unnecessary empiric antimicrobials, some of which can be toxic and interact with other medications being used.
It may be challenging to distinguish between colonization and active infection.
+++
IMMUNOLOGIC DEFICIT: T-CELL INHIBITION LEADS TO INCREASED RISK OF OPPORTUNISTIC INFECTIONS
++
Immunosuppression—although necessary to protect the transplanted liver from rejection—increases the risk of infections.
Most immunosuppressive agents are associated with T-cell depletion, reduced T-cell activation, or inhibition of T-cell proliferation.
The net result of immunosuppression is reduced cell-mediated immunity.
Immunosuppression levels are generally greatest from month 1 to 6 posttransplant, as well as during any subsequent episodes of rejection that require intensified immunosuppression.
Measurement of CD4+ T helper cells is not as predictive of opportunistic infections in transplant recipients as it is in patients with HIV/AIDS.
+++
CLINICAL PREDICTORS OF POSTTRANSPLANT INFECTIONS
++